TRCT
VVOS icon

Tower Research Capital (TRC)’s Vivos Therapeutics VVOS Stock Holding History

Tower Research Capital (TRC)’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37K Sell
5,211
-2,177
-29% -$1.71K ﹤0.01% 4677
2026
Q1 		$8.72K Buy
7,388
+4,423
+149% +$7.09K ﹤0.01% 3957
2025
Q4 		$6.02K Buy
2,965
+171
+6% +$423 ﹤0.01% 4085
2025
Q3 		$8.66K Buy
2,794
+2,297
+462% +$10.4K ﹤0.01% 4047
2025
Q2 		$1.57K Buy
+497
New +$1.25K ﹤0.01% 4788
2025
Q1 		– Sell
-161
Closed -$691 – 5845
2024
Q4 		$691 Sell
161
-1,502
-90% -$5.01K ﹤0.01% 5200
2024
Q3 		$4.34K Sell
1,663
-620
-27% -$1.62K ﹤0.01% 4581
2024
Q2 		$5.07K Buy
2,283
+554
+32% +$1.35K ﹤0.01% 4721
2024
Q1 		$8.35K Buy
1,729
+11
+0.6% +$66 ﹤0.01% 4031
2023
Q4 		$21.4K Buy
+1,718
New +$14.7K ﹤0.01% 3604
2023
Q3 		– Sell
-983
Closed -$12.5K – 6272
2023
Q2 		$12.5K Sell
983
-345
-26% -$3.38K ﹤0.01% 3860
2023
Q1 		$11K Buy
1,328
+651
+96% +$14.2K ﹤0.01% 4276
2022
Q4 		$7K Buy
677
+146
+27% +$2.13K ﹤0.01% 4632
2022
Q3 		$9K Buy
531
+391
+279% +$11.9K ﹤0.01% 4703
2022
Q2 		$5K Sell
140
-12
-8% -$499 ﹤0.01% 5109
2022
Q1 		$10K Sell
152
-66
-30% -$4.32K ﹤0.01% 4361
2021
Q4 		$12K Sell
218
-1,287
-86% -$104K ﹤0.01% 4332
2021
Q3 		$152K Buy
+1,505
New +$158K ﹤0.01% 2062
2021
Q2 		– Sell
-15
Closed -$2K – 5879
2021
Q1 		$2K Buy
+15
New +$2.68K ﹤0.01% 5055

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Tower Research Capital (TRC)'s VVOS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Vivos Therapeutics (VVOS) stake by 29% in Q2 2026, selling an estimated $1.71K and leaving 5,211 shares worth $2.37K. The position accounts for ﹤0.01% of the portfolio, ranked #4677.

Tower Research Capital (TRC) first reported a position in VVOS in Q1 2021 and has held it in 19 quarters since. The position peaked at $152K in Q3 2021. 22 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • Tower Research Capital (TRC) held 5,211 shares of Vivos Therapeutics worth $2.37K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,177 Vivos Therapeutics shares in Q2 2026, an estimated $1.71K.
  • Vivos Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4677 holding.
  • Tower Research Capital (TRC) first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Vivos Therapeutics position peaked at $152K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.